Guildford, United Kingdom

ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.

Investment Perspective

ANGLE successfully navigated a number of regulatory and clinical hurdles during 2022, including breakthrough FDA product clearance for Parsortix, and highly positive ovarian cancer data. Key elements are now largely in place to help deliver on Parsortix’s significant potential within the evolving liquid biopsy field. To realise this, ANGLE is pursuing a multi-pronged strategy to make Parsortix broadly available to industry and patients. The near-term focus is on growing the Pharma services business, attracting industry partnerships for downstream analysis, and completion of the remaining LDT development work. Any one of these could be transformational if successfully executed, and together should lead to multiple layers of future revenue growth. Our updated DCF-based valuation is £253m, equivalent to 97p per share.

Market information

SymbolPrimary exchanges


Revenue building and growth opportunities are developing
Lighthouse | 07 Sep 2023
Recent deals provide evidence of assay traction
Lighthouse | 21 Apr 2023
Pursuing a multi-faceted Parsortix commercial opportunity
Outlook | 13 Mar 2023

Recent News

Interim H123 results
07 Sep 2023
Launch of Portrait Flex assay
04 Sep 2023
Senior management appointments
05 Jun 2023
Pharma services contract with Artios Pharma
25 May 2023